A CML diagnosis, often striking young Indian adults, is now more manageable. This guide emphasizes empowering patients by asking five crucial questions to their oncologist. These queries cover ...
Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback